Our program project represents a highly integrated approach to translate basic science findings on the role of hypoxia in tumor progression and resistance to therapy to pre-clinical models of cancer that we ultimately hope to take into the clinic. The overall hypothesis of this proposal is that hypoxia not only makes tumor cells resistant to therapy, but also increases their invasiveness and metastatic potential by inducing metastatic-related genes such as osteopontin (OPN) and connective tissue growth factor (CTGF). During the last four years, the investigators of this program project have worked together using yeast as well as mammalian cells to understand the genomic response of tumor cells to hypoxia and develop new targeted therapies to eliminate hypoxic cells or inhibit the secreted gene products of hypoxic cells that drive malignant progression. We have advanced understanding of gene regulation under hypoxic conditions, used the yeast deletion pool to identify genetic determinants that are critical for survival under hypoxia as well as other stress inducing conditions, and developed new diagnostics for hypoxia. In the renewal application we will further define critical effectors of the hypoxic response that will be manipulated to increase the effectiveness of new hypoxic cytotoxins as well as inhibit the activity of secreted proteins induced by hypoxia that are essential for tumor growth and expansion. Emphasis is placed on understanding and exploiting the tumor microenvironment of head &neck cancers where overcoming hypoxia is important in achieving local tumor control, and pancreatic cancers where the role of hypoxia in tumor progression has been largely uninvestigated. One way to take advantage of the decreased oxygenation status of a tumor is to administer a hypoxia-activated cytotoxin such as TPZ, which is currently being studied in Phase III clinical trials as a result from previous work in this Program Project. However, newer and more potent hypoxic cytotoxins such as PR-104, that have the additional benefit of producing a bystander effect, will be investigated in combination with cytotoxic agents such as cisplatin, inhibitors of HIF-1 which increase tumor hypoxia by shutting down mitochondrial activity and mAbs directed against CTGF and OPN that act in a cytostatic manner to inhibit tumor growth and metastases. The overall goals of this PPG are to exploit tumor hypoxia therapeutically through the inhibition of specific targets that are induced by hypoxia. Project 1 will investigate the role of HIF and CTGF in regulating tumor growth and metastases. Project 2 will investigate the efficacy of a new hypoxic cytotoxin PR-104 in combination with both cytotoxic and cytostatic agents. Project 3 will investigate mitochondrial regulation by hypoxia in yeast and mammalian cells and determine whether inhibition of HIF will increase the efficacy of hypoxic cytotoxins. Project 4 will examine the role of OPN in modulating tumor growth and metastasis. Project 5 will determine the importance of the three major signaling pathways activated by the unfolded protein response for tumor growth and adaptation to hypoxia. Few groups could be better positioned to use yeast and mammalian genetics to develop novel hypoxia based therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA067166-15S1
Application #
8492948
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (O2))
Program Officer
Bernhard, Eric J
Project Start
1997-04-01
Project End
2013-01-31
Budget Start
2011-02-01
Budget End
2013-01-31
Support Year
15
Fiscal Year
2012
Total Cost
$118,350
Indirect Cost
$43,789
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Vilalta, Marta; Brune, Jourdan; Rafat, Marjan et al. (2018) The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration. Clin Exp Metastasis 35:247-254
Tandon, Neha; Thakkar, Kaushik N; LaGory, Edward L et al. (2018) Generation of Stable Expression Mammalian Cell Lines Using Lentivirus. Bio Protoc 8:
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
Benej, Martin; Hong, Xiangqian; Vibhute, Sandip et al. (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115:10756-10761
Rafat, Marjan; Aguilera, Todd A; Vilalta, Marta et al. (2018) Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. Cancer Res 78:4241-4252
Saiki, Julie P; Cao, Hongbin; Van Wassenhove, Lauren D et al. (2018) Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. Proc Natl Acad Sci U S A 115:6279-6284
Olcina, Monica M; Kim, Ryan K; Melemenidis, Stavros et al. (2018) The tumour microenvironment links complement system dysregulation and hypoxic signalling?. Br J Radiol :20180069
Boyko, Tatiana V; Bam, Rakesh; Jiang, Dadi et al. (2017) Inhibition of IRE1 results in decreased scar formation. Wound Repair Regen 25:964-971
Yuan, William; Jiang, Dadi; Nambiar, Dhanya K et al. (2017) Chemical Space Mimicry for Drug Discovery. J Chem Inf Model 57:875-882
Aguilera, Todd A; Giaccia, Amato J (2017) Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase. Clin Cancer Res 23:2928-2933

Showing the most recent 10 out of 203 publications